Diabetic macular edema: Upcoming therapies

Yan A., Jones C., DEMİREL S., Chhablani J.

Graefe's Archive for Clinical and Experimental Ophthalmology, 2024 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1007/s00417-024-06595-7
  • Dergi Adı: Graefe's Archive for Clinical and Experimental Ophthalmology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, Veterinary Science Database
  • Anahtar Kelimeler: Anti-VEGF, Diabetic macular edema, Diabetic macular edema therapy, Diabetic retinopathy, Gene therapy
  • Ankara Üniversitesi Adresli: Evet

Özet

Abstract: Diabetic macular edema (DME) is a serious vision-threatening complication that can arise at any stage of diabetic retinopathy. Primary treatment involves anti-vascular endothelial growth factor (VEGF) agents, which are highly effective but associated with challenges, such as the need for frequent injections, relapses, and resistance to therapy. Therefore, there has been a growing interest in developing new treatments that offer similar or superior outcomes in DME. This review article explores emerging treatments, including WNT agonists, gene therapy, protein inhibitors, and, most importantly, the first-ever non-invasive and oral drugs. The evolving therapies in diabetic retinopathy offer hope for continued improvement in vision loss associated with one of the most common chronic conditions worldwide.